US Stock Insider Trading | Rapport disclosed 8 insider trading transactions on February 19

K-LinePoet · 2026-02-24T00:08:35+00:00

On February 19, 2026, Rapport disclosed insider trading activities involving executives Bredt David and director Ceesay Abraham. Bredt sold 5,400 shares on February 17 and bought 6,000 shares on February 19. Ceesay sold multiple transactions on February 18, totaling approximately 11,000 shares. Rapport is a clinical-stage biopharmaceutical company focused on the development of drugs for central nervous system diseases.

K-LinePoet

2026-02-24 00:08:35

Abstract generation in progress

On February 19, 2026, Rapport (RAPP) disclosed eight insider trading transactions. Executive Bredt David purchased 6,000 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 19, 2026	Executive	Bredt David	February 17, 2026	Sell	5,400	28.95	156,300
February 19, 2026	Executive	Bredt David	February 17, 2026	Sell	2,200	29.59	65,100
February 19, 2026	Executive	Bredt David	February 17, 2026	Sell	900	28.02	25,200
February 19, 2026	Executive	Bredt David	February 19, 2026	Buy	6,000	1.80	10,800
February 19, 2026	Director	Ceesay Abraham	February 18, 2026	Sell	3,552	29.05	103,200
February 19, 2026	Director	Ceesay Abraham	February 18, 2026	Sell	2,983	29.04	86,600
February 19, 2026	Director	Ceesay Abraham	February 18, 2026	Sell	2,100	29.80	62,600
February 19, 2026	Director	Ceesay Abraham	February 18, 2026	Sell	2,281	29.80	68,000
January 22, 2026	Director	Ceesay Abraham	January 20, 2026	Sell	5,833	26.12	152,300
January 22, 2026	Director	Ceesay Abraham	January 20, 2026	Sell	5,083	26.11	132,700

[Company Profile]

Rapport Therapeutics, Inc. was incorporated in Delaware in February 2022 under the name Precision Neuroscience NewCo, Inc., and renamed Rapport Therapeutics, Inc. in October 2022. The company is a clinical-stage biopharmaceutical company focused on discovering and developing translational small molecule drugs for patients with central nervous system (“CNS”) diseases, aiming to become a leader in precision neuroscience.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.